← Back to Search

Antisense Oligonucleotide

QR-421a for Retinitis Pigmentosa

Phase 2 & 3
Waitlist Available
Research Sponsored by ProQR Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 27 months
Awards & highlights

Summary

This trial is testing a new treatment for Retinitis Pigmentosa that involves injecting a medication into the eye. The study will evaluate how well the medication works and how safe it is.

Eligible Conditions
  • Retinitis Pigmentosa
  • Retinal Disease
  • Usher Syndrome
  • Deafblind
  • Eye Diseases
  • Congenital Eye Disorders
  • Vision Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~27 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 27 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Mean Sensitivity
Secondary outcome measures
Change From Baseline in Best Corrected Visual Acuity (BCVA)
Change From Baseline in Full-field Stimulus Threshold (FST)
Change From Baseline in Low Luminance Visual Acuity (LLVA)
+8 more
Other outcome measures
Change From Baseline in Mobility Course Score

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: QR-421a 60/60 µgExperimental Treatment1 Intervention
60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
Group II: QR-421a 180/60 µgExperimental Treatment1 Intervention
180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
Group III: Sham-procedurePlacebo Group1 Intervention
Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QR-421a
2019
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

ProQR TherapeuticsLead Sponsor
11 Previous Clinical Trials
292 Total Patients Enrolled
4 Trials studying Retinitis Pigmentosa
133 Patients Enrolled for Retinitis Pigmentosa
ProQR Clinical Trial ManagerStudy DirectorProQR Therapeutics
3 Previous Clinical Trials
112 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
112 Patients Enrolled for Retinitis Pigmentosa
ProQR Medical MonitorStudy DirectorProQR Therapeutics
7 Previous Clinical Trials
172 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
112 Patients Enrolled for Retinitis Pigmentosa
~1 spots leftby Jun 2025